CRIS Current Research Information System

CECI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.969
AS - Asia 5.673
EU - Europa 3.715
AF - Africa 355
SA - Sud America 323
OC - Oceania 9
AN - Antartide 1
Totale 16.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.881
VN - Vietnam 1.735
SG - Singapore 1.457
CN - Cina 1.243
GB - Regno Unito 921
IT - Italia 715
DE - Germania 466
HK - Hong Kong 426
SE - Svezia 421
FR - Francia 267
IN - India 249
BR - Brasile 229
RU - Federazione Russa 228
IE - Irlanda 145
ZA - Sudafrica 113
BD - Bangladesh 108
NL - Olanda 100
FI - Finlandia 96
KR - Corea 95
TG - Togo 86
JP - Giappone 79
EE - Estonia 74
CI - Costa d'Avorio 70
JO - Giordania 65
CA - Canada 62
CH - Svizzera 57
UA - Ucraina 48
AR - Argentina 44
BG - Bulgaria 40
BE - Belgio 29
SC - Seychelles 29
IR - Iran 27
TH - Thailandia 27
ID - Indonesia 26
PL - Polonia 23
NG - Nigeria 22
AT - Austria 20
ES - Italia 20
PH - Filippine 20
EC - Ecuador 19
MX - Messico 19
IQ - Iraq 16
TR - Turchia 16
TW - Taiwan 15
SA - Arabia Saudita 11
CL - Cile 10
PK - Pakistan 10
MY - Malesia 9
UZ - Uzbekistan 9
AU - Australia 8
LT - Lituania 8
RO - Romania 8
VE - Venezuela 7
CO - Colombia 6
EG - Egitto 6
ET - Etiopia 6
AL - Albania 5
KZ - Kazakistan 5
MA - Marocco 5
CZ - Repubblica Ceca 4
GR - Grecia 4
LB - Libano 4
TN - Tunisia 4
DK - Danimarca 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GA - Gabon 2
KE - Kenya 2
KG - Kirghizistan 2
PE - Perù 2
PS - Palestinian Territory 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
AQ - Antartide 1
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
GE - Georgia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 16.040
Salva come PNG Salva come JPEG
Città #
Singapore 1.015
Southend 826
Ashburn 683
Fairfield 605
Hong Kong 406
Chandler 405
San Jose 340
Santa Clara 285
Ho Chi Minh City 277
Seattle 274
Houston 267
Wilmington 266
Woodbridge 259
Hanoi 238
Cambridge 229
Princeton 184
Beijing 162
Hefei 162
Dublin 145
Ann Arbor 133
Bologna 133
Dong Ket 124
Lauterbourg 113
Boardman 109
Los Angeles 100
Westminster 90
New York 88
Lomé 86
Helsinki 83
Nanjing 73
Seoul 73
Berlin 71
Abidjan 70
Padova 68
Amman 64
Tokyo 58
Milan 57
Redondo Beach 51
Da Nang 46
Dallas 46
Bern 45
Buffalo 42
Jinan 42
Shenyang 40
São Paulo 40
Haiphong 39
Munich 39
Council Bluffs 38
Sofia 36
Florence 34
Turin 34
Saint Petersburg 33
Guangzhou 31
San Diego 31
Changsha 30
Rome 30
Frankfurt am Main 29
Medford 29
Brussels 27
Hebei 27
Nanchang 27
Toronto 27
Johannesburg 26
Bremen 25
Redwood City 23
Tianjin 22
Chicago 21
Nuremberg 21
Abeokuta 20
London 20
Orem 20
Zhengzhou 20
Phoenix 19
Bengaluru 17
Biên Hòa 15
Brooklyn 15
Norwalk 15
Amsterdam 14
Dearborn 14
Jiaxing 14
San Francisco 14
Warsaw 14
Yubileyny 14
Falkenstein 13
Mumbai 13
Shanghai 13
Falls Church 12
Taiyuan 12
The Dalles 12
Thái Bình 12
Vienna 12
Atlanta 11
Shenzhen 11
Taizhou 11
Baghdad 10
Des Moines 10
Hangzhou 10
Jakarta 10
Montreal 10
Quận Bình Thạnh 10
Totale 10.089
Salva come PNG Salva come JPEG
Nome #
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 345
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence 271
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 235
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 229
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 225
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 225
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 224
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 218
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 216
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 210
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 209
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 209
68Ga-PSMA PET/CT for restaging prostate cancer after definitive therapy: Results of a prospective single-center trial 206
11C-Choline PET/CT for Restaging of Bladder Cancer 205
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 196
18f-fdg pet/ct for restaging gastric cancer after surgical resection 195
68Ga-PSMA PET/CT in prostate cancer 193
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 191
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 191
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 189
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 189
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 188
18F-FACBC PET/CT in comparison to 11c-choline for the detection of prostate cancer relapse after radical prostatectomy: A perspective study in 50 patients 186
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 184
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 183
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 182
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment 176
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 176
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 173
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 172
PET/CT and prostate cancer 169
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 165
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 164
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications 163
18F-FACBC PET/CT VS. 11C-CHOLINE FOR THE DETECTION OF PROSTATE CANCER RELAPSE AFTER RADICAL TREATMENT 163
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 163
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 163
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 163
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT IN COMPARISON WITH CONTRASTENHANCED CT IN THE PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER USING THE PATHOLOGICAL SPECIMENS AS REFERENCE STANDARD 162
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 162
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 160
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 158
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT COMPARED TO CONTRASTENHANCED CT IN THE POSTOPERATIVE RESTAGING OF RECURRENT BLADDER CANCER: ANALYSIS OF 20 CONSECUTIVE PATIENTS 158
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 154
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. 153
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. 152
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 152
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. 152
New radiopharmaceutical markers for metabolism and receptor 151
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 151
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 151
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml 150
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 149
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 148
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 147
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 147
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 144
Yttrium 90 Intra Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5 Year Experience at a Single Center 144
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 143
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 141
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: preliminary results 141
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis 140
PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT? 139
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. 135
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 134
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report 133
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study 133
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 131
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT 130
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. 129
Role of 18F-FDG PET/CT in the restaging of patients affected by clear cell renal carcinoma 128
Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. 128
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. 127
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer 125
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. 125
New aspects of molecular imaging in prostate cancer. 124
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. 124
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 124
Molecular Imaging and Precision Medicine in Prostate Cancer 122
PET/CT in prostate cancer 122
null 119
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 119
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. 119
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 118
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 116
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 113
null 113
Therapy assessment in prostate cancer using choline and PSMA PET/CT. 111
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 109
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy 109
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 108
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 107
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence 102
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 100
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 99
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 92
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer 92
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 89
New radiopharmaceutical Markers for Matebolism and receptor 88
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer 86
Totale 15.536
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.125
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.125
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021371 0 0 0 0 0 0 0 0 0 0 0 371
2021/20221.983 554 58 97 126 170 78 49 114 62 59 357 259
2022/20231.949 172 288 112 254 115 133 50 103 386 89 145 102
2023/2024555 75 85 26 54 39 90 30 34 22 42 29 29
2024/20252.341 114 344 173 187 430 151 131 49 24 122 108 508
2025/20265.388 482 398 418 361 577 269 503 232 1.137 505 285 221
Totale 16.350